Patient Access Services (PAS) – HEOR, RWE, PRMA and Scientific Communications Consulting

In this progressing and increasingly competitive commercial landscape, attaining optimal market access is becoming extra challenging for pharmaceutical/medical device patrons. In the stir of the global economic crisis, ever-increasing costs and abating healthcare budgets, payers (both national and local) have a significant and growing influence on a product's commercial success. The need to demonstrate clinical and economic evidence of a product to providers, healthcare decision-makers and payers is becoming the central component to a product's success.

PAS services outsourcing is an attractive strategy when specialised skills are required for varying study types and India has always been considered as a preferred destination due to cost effectiveness, better time management and utmost quality of deliverables.

MarksMan Healthcare Solutions (ISO 27001:2013), a non-profit division of path finders charitable trust, is an International knowledge-based Patient Access Services (PAS) and Scientific Communications consulting firm based in Navi Mumbai, India. We provide services pertaining to “Health Economics and Outcomes Research (HEOR), Real World Evidence (RWE), Pricing Reimbursement and Market Access (PRMA) and Scientific Communications" to maximize the opportunities of pharmaceutical products during a decision making process.

The foundation of MarksMan services is to provide clinical and economic evidence that aims to support our client's product positioning, Health Technology Assessment (HTA) and reimbursement. Our expertise lies in developing product value evidence such as clinical efficacy, real-world data, patient quality of life reports, and opportunity cost of various treatment mixes, budget impact, and cost-effectiveness models.

Insights given by MarksMan can provide provable evidence for payers and can help pharmaceutical companies to overcome the evolving market access challenges. This adds lot of value both to the industry and the patients, who ultimately experience better health outcomes.

MEET THE TEAM


LATEST FROM BLOG


26Apr 2017

All branded drugs are of good quality – Fiction Majority of the branded drugs are of good quality – Fact All generic drugs are of good quality – Fiction Majority of the generic drugs are of good quality – Fact All pharma companies take pro-patient initiatives – Fiction Few pharma companies take pro-patient initiatives – […]

10Apr 2017

Bioresorbable stents have effectively been pulled from the European market by Abbott and will now be available only in “clinical registry setting at select sites/institutions” in Europe, where they will be monitored till a review in 2018. India has been among the largest markets for these stents in recent years. The development comes in the […]

31Mar 2017

According to the World Health Organization (W.H.O), there is currently no universally agreed definition among its member states in what is widely known as ‘Counterfeit medicines’. Nevertheless, W.H.O does indicate that the term ‘counterfeit’ is widely used to include falsified, unlicensed, falsely packaged, stolen and substandard medical products. Jurisdictions across the world define counterfeit medicines […]


Latest Publications

Updated list of scientific publications that our writers have successfully achieved post getting associated with us (MarksMan and Geronimo) since year 2012 

  1. 1
    Efficacy and Safety of Canagliflozin Among Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

    Kaur K, Likar N, Dang A, Kaur G. Efficacy and Safety of Canagliflozin Among Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Indian J Endocr Metab 2015;19:705-21

  2. 2
    Phytomedicine in the Treatment of Cancer: A Health Technology Assessment.

    Chaudhary T, Chahar A, Sharma JK, Kaur K, Dang A. Phytomedicine in the Treatment of Cancer: A Health Technology Assessment. J Clin Diagn Res. 2015 Dec;9(12):XC04-XC09

  3. 3
    A Post-marketing Study Evaluating the Lipid Altering Efficacy and Safety of Approved Dose Ranges of Rosuvastatin in Indian Hyperlipidemia Patients in Routine Clinical Practice (ROSUVEES).

    Shah CP, Kumbla DK, Moorthy A, Murthy S, Aneja P, Gotur J, Gupta A, Abhi R, Bansal R, Sonawala S, Balani AG, Kedarnathan R, Soni P, Chinnaiyann P. A post-marketing study evaluating the lipid-altering efficacy and safety of approved dose ranges of rosuvastatin in Indian hyperlipidemia patients in routine clinical practice (ROSUVEES). JICC 2015; 5(4): 282-290 

  4. 4
    Reduced Risk of Parkinson’s Disease in Users of Calcium Channel Blockers: A Meta-analysis.

    K Gudala, R Kanukula, D Bansal. Reduced Risk of Parkinson’s Disease in Users of Calcium Channel Blockers: A Meta-analysis. International Journal of chronic diseases. Volume 2015 (2015), Article ID 697404, 7 

  5. 5
    Effectiveness and Safety of Fixed Dose Combination of Acarbose/metformin in Indian Type 2 Diabetes Patients: Results from Observational GLOBE Study.

    Saboo B, Reddy GC, Juneja S, Kedia AK, Manjrekar P, Rathod R. Effectiveness and Safety of Fixed Dose Combination of Acarbose/metformin in Indian Type 2 Diabetes Patients: Results from Observational GLOBE Study. Indian J Endocr Metab 2015;19:129-35

More